Core Viewpoint - The merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd. has been approved by NLS shareholders, paving the way for the formation of NewCelX Ltd., which will be listed on Nasdaq under the ticker "NCEL" [1][6][7]. Group 1: Merger Details - The merger will create a Nasdaq-listed company named NewCelX, with governance and capital structure approvals completed [2]. - Kadimastem shareholders will own 84.4% of the combined company, while NLS shareholders will own 15.6%, reflecting the relative value contributions of each party [5][6]. - The combined company will integrate Kadimastem's advanced cell therapy programs with NLS's expertise in CNS small-molecule therapies [2][7]. Group 2: Leadership and Governance - The leadership team will be headed by Ronen Twito as Executive Chairman and CEO, with Prof. Michel Revel serving as Chief Scientific Officer and Director [3][6]. - A new Board of Directors will be elected, and various committees will be newly constituted to enhance governance and execution [6]. Group 3: Clinical Programs and Pipeline - The merger will unite Kadimastem's clinical programs, including a Phase 2a ALS trial of AstroRx® and the IsletRx diabetes product candidate, with NLS's CNS therapies [7]. - The combined company aims to build a diversified biotechnology portfolio with the potential to deliver transformative therapies to patients worldwide [7].